CN111825754B - 一种从芝麻蛋白中获得的具有降血压与降血糖活性的多肽 - Google Patents
一种从芝麻蛋白中获得的具有降血压与降血糖活性的多肽 Download PDFInfo
- Publication number
- CN111825754B CN111825754B CN202010687265.9A CN202010687265A CN111825754B CN 111825754 B CN111825754 B CN 111825754B CN 202010687265 A CN202010687265 A CN 202010687265A CN 111825754 B CN111825754 B CN 111825754B
- Authority
- CN
- China
- Prior art keywords
- sesame
- polypeptide
- sesame protein
- adjusting
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000207961 Sesamum Species 0.000 title claims abstract description 78
- 235000003434 Sesamum indicum Nutrition 0.000 title claims abstract description 78
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 72
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 62
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 57
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 35
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 35
- 239000008280 blood Substances 0.000 title claims abstract description 20
- 210000004369 blood Anatomy 0.000 title claims abstract description 20
- 230000000694 effects Effects 0.000 title claims abstract description 20
- 230000036772 blood pressure Effects 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 16
- 150000001413 amino acids Chemical class 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 238000000746 purification Methods 0.000 claims abstract description 6
- 238000000926 separation method Methods 0.000 claims abstract description 6
- 238000010532 solid phase synthesis reaction Methods 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims abstract description 5
- 235000013305 food Nutrition 0.000 claims abstract description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000012153 distilled water Substances 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 7
- 108090000317 Chymotrypsin Proteins 0.000 claims description 6
- 108090000631 Trypsin Proteins 0.000 claims description 6
- 102000004142 Trypsin Human genes 0.000 claims description 6
- 229960002376 chymotrypsin Drugs 0.000 claims description 6
- 238000005238 degreasing Methods 0.000 claims description 6
- 238000001728 nano-filtration Methods 0.000 claims description 6
- 239000012588 trypsin Substances 0.000 claims description 6
- 238000004440 column chromatography Methods 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 239000012466 permeate Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 229920005654 Sephadex Polymers 0.000 claims description 4
- 239000012507 Sephadex™ Substances 0.000 claims description 4
- 230000017854 proteolysis Effects 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 229920001503 Glucan Polymers 0.000 claims description 3
- 102000057297 Pepsin A Human genes 0.000 claims description 3
- 108090000284 Pepsin A Proteins 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000011033 desalting Methods 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 229940088598 enzyme Drugs 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- 229940111202 pepsin Drugs 0.000 claims description 3
- 239000012071 phase Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 claims description 2
- 230000010030 glucose lowering effect Effects 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 208000001953 Hypotension Diseases 0.000 claims 1
- 208000021822 hypotensive Diseases 0.000 claims 1
- 230000001077 hypotensive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 230000036541 health Effects 0.000 abstract description 4
- 238000012545 processing Methods 0.000 abstract description 3
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 24
- 239000000243 solution Substances 0.000 description 15
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 11
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 11
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 11
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 11
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 11
- 230000001603 reducing effect Effects 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000001972 liquid chromatography-electrospray ionisation mass spectrometry Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- LGURYBCSJPXHTF-UHFFFAOYSA-N 2-(2,4-dichlorophenoxy)ethyl benzoate Chemical compound ClC1=CC(Cl)=CC=C1OCCOC(=O)C1=CC=CC=C1 LGURYBCSJPXHTF-UHFFFAOYSA-N 0.000 description 2
- DVIVBKYEWHNZPU-QWRGUYRKSA-N CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)CC(=O)O Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)CC(=O)O DVIVBKYEWHNZPU-QWRGUYRKSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000046095 Psophocarpus tetragonolobus Species 0.000 description 2
- 235000010580 Psophocarpus tetragonolobus Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- 101710194913 11S globulin seed storage protein 2 Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 101800000068 Antioxidant peptide Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 101000773743 Homo sapiens Angiotensin-converting enzyme Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- LGWQQSRBCPQEER-JEDNCBNOSA-N [N+](=O)([O-])C1=CC=C(N)C=C1.NCC(=O)N1[C@@H](CCC1)C(=O)O Chemical compound [N+](=O)([O-])C1=CC=C(N)C=C1.NCC(=O)N1[C@@H](CCC1)C(=O)O LGWQQSRBCPQEER-JEDNCBNOSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 108010058865 angiotensinase Proteins 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000045598 human DPP4 Human genes 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 108010004495 kininase IV Proteins 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 231100001223 noncarcinogenic Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/045—Organic compounds containing nitrogen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Botany (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明属于农产品深加工技术领域,具体涉及一种芝麻活性多肽,该多肽由5个氨基酸组成,其序列为:His‑Pro‑Ser‑Pro‑Arg(HPSPR)。本发明芝麻多肽既能通过酶解芝麻蛋白分离纯化后获得,也可以采用化学固相合成方法人工合成。通过测定ACE抑制活力与DPP‑IV抑制活力发现:该多肽具有降血压与降血糖活性,可以作为功能成分用于制备药物、保健品、食品、日化用品等领域,具有广阔的市场前景。
Description
技术领域
本发明属于植物蛋白深加工技术领域,具体涉及一种来源于芝麻11S蛋白前体2的活性多肽HPSPR、制备方法以及其具有的抗氧化与降血糖活性应用。
背景技术
目前,非传染慢性疾病(高血压、高血脂、糖尿病等)成为亟待解决的全球公共卫生问题。我国是高血压与糖尿病的高发国家。高血压与糖尿病及其它们的并发症,具有病程长、难以治愈、后遗症重等特点,不但加重国家卫生与家庭经济负担,也严重影响患者的生活质量。为治疗高血压与糖尿病,人类开发多种药物,这些药物虽然具有起效快等优点,但均有一定的副作用,长期服用对人体有一定的危害。
为了减少或替换某些人工合成药物的使用,科研人员从水解食源蛋白中发现具有降血压肽、降糖肽(DPP-IV抑制肽),这些活性肽具有作用平缓、安全性高等优点。然而上述多肽多只针对某一靶点,如人体血管紧张素转换酶(ACE)或二肽激肽酶-IV(DPP-IV),而糖尿病与高血压往往呈现并发现象,因此,只针对某一靶点的活性肽,难以有效的预防与减缓高血压或糖尿病的发生发展。有科研人员从鸵鸟蛋蛋白、扁豆蛋白的水解液中发现多活性肽存在,如扁豆蛋白水解物具有降血压与抗氧化活性。因此,可以推测自然界中存在具有降血压与降血糖的多活性肽。将上述多肽应用于预防或辅助治疗高血压与糖尿病具有积极的社会价值与光明的市场价值。
芝麻是我国居民喜爱的日常食物之一,年消费芝麻在150万吨左右。传统与现代医学认为芝麻具有营养保健功能,其营养保健功能除了芝麻素的贡献以外,作为芝麻的主要成分——芝麻蛋白也有贡献,其酶解物中发现抗氧化肽、降血压肽、螯合金属肽。为推动芝麻资源的充分利用,提高芝麻蛋白加工附加值,满足居民健康生活的需求,有必要开发具有降血压与降血糖的芝麻双活性肽。
发明内容
为满足人民健康生活的需求、替代人工合成的有毒副作用的降血压药与降血糖药,本发明目的在于提供一种来自芝麻蛋白的同时具有降血压和降血糖活性的多肽,该芝麻多肽具有活性高、制备工艺成熟,成本可控等优点,具有广阔的市场前景。
本发明还提供了上述芝麻多肽的制备方法,以及其在制备具有降血压和/或降血糖药物方面的应用。
为实现上述目的,本发明采用以下技术方案:
一种从芝麻蛋白中获得的具有降血压与降血糖活性的多肽,该多肽由5个氨基酸组成,其序列为:His-Pro-Ser-Pro-Arg(HPSPR,HR-5),源自芝麻11S蛋白前体2(11Sglobulin seed storage protein 2 precursor,11S_SESIN)。具体的,HPSPR源自芝麻11S蛋白前体2的88-92处,即SLPNYHPSPRLVYIE 88-92。
本发明公开了一种上述多肽的制备方法,其可以通过人工化学合成制备,如采用固相合成法按照本领域常规工艺制备多肽。
本发明还公开了一种从芝麻蛋白中提取上述多肽的方法,其通过蛋白酶解、分离纯化等步骤制得;具体包括下述步骤:
1)芝麻蛋白提取:
将除杂后的芝麻粉碎、脱脂,加入蒸馏水,调节pH到10-12,离心后,收集上清液,调节pH到4-5,离心,收集沉淀,水洗,冷冻干燥,获得芝麻蛋白;
2)蛋白酶解:
将步骤1)所得芝麻蛋白,按1g:10-30 mL(w/v)加入蒸馏水获得芝麻蛋白溶液,90-100 ℃加热15-40 min,冷却至室温,将pH值调至1.5-2.5,加入芝麻蛋白质量0.5-2.5% (w/w)的胃蛋白酶,于30-50 ℃搅拌酶解2-6 h,随后调节pH至7.5-9.0,加入芝麻蛋白质量0.5-2.5% (w/w)胰糜蛋白酶,于30-50 ℃酶解2-8 h,调节pH至4.0-4.5,8000-10000 r/min离心取上清液,4-10℃低温备用;
3)分离纯化:
将步骤2)所得上清液调节pH到7.0,采用两级超滤处理,透过液采用纳滤进行脱盐浓缩,然后采用葡聚糖凝胶柱层析法分离纯化,收集保留时间在275-330 min的组分,冷冻真空干燥即得。将冷冻干燥获得的多肽样品,通过Nano-LC-ESI-MS/MS进行分析鉴定,鉴定具有降血压与降血糖活性的多肽的氨基酸序列为:His-Pro-Ser-Pro-Arg(HPSPR)。HPSPR源自芝麻11S蛋白前体2(11S_SESIN)88-92处,即SLPNYHPSPRLVYIE 88-92。
具体的,步骤2)中所述胰糜蛋白酶由酶活之比为6:1的胰蛋白酶与胰凝乳蛋白酶组成。
具体的,步骤3)中所述的两级超滤中,一级超滤所采用的超滤膜截留分子量为3000-10000 Da, 二级超滤所采用的超滤膜截留分子量为1000 Da,一级超滤的透过液进行二级超滤,其中一级超滤的操作压力为1 Mpa-3 Mpa,二级超滤的操作压力为1.5 MPa-3.5MPa。
具体的,步骤3)中葡聚糖凝胶柱层析法分离纯化条件:层析柱100×1.8 cm,流动相为蒸馏水,流速1.5 mL/min,上样量为5 mL,检测波长为280 nm,收集峰III (时间275-330 min)。
进一步优选的,步骤3)中选用的是葡聚糖G-10,粒径40-120 µm。
具体的,步骤1)中芝麻脱脂采用溶剂萃取法或亚临界萃取法,溶剂萃取时,采用石油醚、正已烷或乙醚进行脱脂;亚临界萃取时,采用丁烷、丙烷脱脂。提取蛋白时,按照料液比(w/v)为1g:6-30 mL加入蒸馏水。采用氢氧化钠将pH调节为10-12,室温搅拌30-90 min。离心条件为:3500-5000 r/min离心20-40 min;采用盐酸将上清液的pH调至4-5。
本发明还提供了上述多肽作为主要功能成分在制备降血压和/或降血糖药物、保健品、食品、日化用品等领域中的应用。
与现有技术相比,本发明具有如下优点:
1)本发明所用的原料为芝麻或低温芝麻饼粕,来源广泛,有成本优势且不影响其他芝麻组分利用,同时,产品附加值高,具有开发利用价值;
2)本发明提供的芝麻活性多肽,安全性高(见附表2),且具有降血压和/或降血糖活性功效;
3)本发明提供的芝麻多肽活性显著,不仅可以作为食品添加剂,也可以作为功能性成分应用于药物、保健品及日化用品中。
附图说明
图1为实施例1葡聚糖柱层析的谱图;
图2为实施例1提取所得芝麻多肽样品在Nano-LC-ESI-MS/MS中的二级质谱图;
图3为实施例2中人工合成活性多肽的HPLC图;
图4为实施例2中人工合成活性多肽的质谱图;
图5为芝麻多肽HPSPR与人体血管紧张素酶的对接图;
图6为芝麻多肽HPSPR与人体DPP-IV的对接图。
具体实施方式
以下结合实施例和附图,对本发明的技术方案作进一步地详细介绍,但本发明的保护范围并不局限于此。基于本发明中的实施例,本领域普通技术人员未做出创造性劳动前提下所获得的其他实施例,都属于本发明的保护范围。
实施例1
一种从芝麻蛋白中提取芝麻多肽的方法,其具体包括如下步骤:
1)芝麻蛋白提取:
取2 kg无杂质和霉粒的芝麻,粉碎至60目,采用索氏抽提器进行脱脂,脱脂条件为:石油醚(沸程30-60 ℃)在60℃脱脂10 h。将脱脂后的芝麻粉按料液比(w/v)1 g:25 mL加入蒸馏水,用NaOH将pH调节为12,室温搅拌90 min进行蛋白提取,随后4500 r/min离心30min,取上清液,调节pH到4.3,4500 r/min离心30 min,收集沉淀,用蒸馏水水洗3次,-60℃冷冻干燥,获得芝麻蛋白,密封备用。
2)蛋白酶解:
将步骤1)所得芝麻蛋白按料液比1 g:25 mL(w/v)加入蒸馏水获得芝麻蛋白溶液,100℃加热20 min,冷却至室温,调节pH至2.0,加入芝麻蛋白质量1.5%(w/w)的胃蛋白酶,37℃搅拌酶解6 h;随后调节pH至8.0,加入芝麻蛋白质量1.5%(w/w)胰糜蛋白酶,37℃酶解8h,随后调节pH至4.3,8000 r/min离心30 min,收集上清液。所述胰糜蛋白酶由酶活之比为6:1的胰蛋白酶与胰凝乳蛋白酶组成。
3)分离纯化
将步骤2)所得上清液调节至pH为7.0,采用两级超滤处理,一级超滤条件为:操作压力1.5 MPa,超滤膜为3000 Da。一级超滤的透过液采用二级超滤处理,二级超滤操作压力为3 MPa,超滤膜为1000 Da。二级超滤的透过液采用纳滤进行脱盐浓缩(纳滤膜截留分子量为200 Da),浓缩至原始料液体积的10%后,加入蒸馏水恢复至原始体积,随后再次纳滤浓缩脱盐,重复上述操作三次,随后收集纳滤截留液;取5 mL上样到葡聚糖G-10层析柱上(100×1.8 cm),流速1.5 mL/min,流动相为蒸馏水,检测波长为280 nm,收集保留时间为275-330min的峰III组分(见图1),-60 ℃冷冻干燥24-48 h,获得芝麻多肽产品。
将多肽样品通过Nano-LC-ESI-MS/MS进行分析鉴定(见图2),鉴定具有降血压与降血糖活性的多肽的氨基酸序列为:His-Pro-Ser-Pro-Arg(HPSPR)。
实施例2
一种人工合成芝麻多肽的方法,其采用固相合成法人工合成。基本流程如下:首先将一个氨基被Fm℃基团保护的氨基酸连接在不溶性固相载体Wang树脂上,然后脱掉氨基的保护基,第一个氨基酸即连接到固相载体上了;其次将氨基被Fm℃基团保护的第二个氨基酸的羧基用缩合剂活化,活化后的氨基酸再与已接在固相载体的第一个氨基酸的氨基反应形成肽键,此时在固相载体上就生成了一个带有保护基的二肽。重复上述的肽键形成反应,使肽链从C端向N端生长,直至达到所需要的肽链长度,最后切割得到目的多肽His-Pro-Ser-Pro-Arg(HPSPR)。合成的芝麻多肽序列的液相质谱分析图见图3和图4,此高纯度合成肽的主要离子峰质荷比为592.66,符合需要合成序列的分子量,说明固相合成成功。
上述采用固相合成法合成芝麻多肽的具体过程参见:①黄惟德、陈常庆著,多肽合成,科学出版社,1985年。②.N.休厄德、H.D.贾库布克著,刘克良等译,肽:化学与生物学,科学出版社,2005年。),该芝麻多肽也可以委托相应的多肽生物公司进行合成,因其化学合成过程不是本申请的重点所在,故本申请此处不再对化学合成过程进行详细赘述。
降血压与降血糖活性应用试验
下述应用试验中,ACE抑制能力(降血压)与DPP-IV抑制能力(降血糖)的测定参照如下进行。HPSPR多肽溶液为将冻干或人工合成的芝麻多肽HPSPR,加入蒸馏水稀释,配成一定浓度的水溶液。
1)ACE抑制能力测定:
取20 μL 1 mg/mL的HPSPR多肽溶液与40 μL 血管紧张素转换酶(ACE)(12.5 mμ/mL)和40 μL 4.66 mmol/L 马尿酰-组氨酰-亮氨酸(HHL)溶液(含0.6 mol/L 氯化钠的0.4mmol/L pH8.5磷酸缓冲液)混合,在37℃反应1 h后,加入150 μL 1.2 mol/L NaOH终止反应,接着加入40 μL 2%的邻苯二甲醛(OPA)甲醇溶液室温反应20 min,随后加入40 mL 6mol/L HCl终止反应。将反应液按1:15 加入蒸馏水稀释后,倒入荧光比色皿,设定激发波长340 nm,发射波长455 nm,狭缝宽度5 nm,测定荧光强度。随后按照下面公式进行计算:
式中:a是含有HPSPR、ACE和HHL溶液的荧光强度,b是ACE和HHL溶液的荧光强度,c是多肽和HHL溶液的荧光强度,d是HHL溶液的荧光强度。
2)DPP-IV抑制能力测定:
取甘氨酰脯氨酸对硝基苯胺(Gly-Pro-p-nitroanilide)加入到100 mmol/L pH8的Tris-HCl缓冲液中配成1.6 mmol/L的溶液,取25 μL加入到96孔板中,加入25 μL 1 mg/mL 的HPSPR多肽溶液 (溶剂是100 mmol/L pH8的Tris-HCl缓冲液),在37 ℃预热10 min,加入50 μL 8 U/L的二肽基肽酶IV (DPP-IV),混匀后,在37 ℃反应60 min,加入100 μL 1mol/L pH4.0的乙酸缓冲液终止酶反应,采用酶标仪测定405 nm的吸光度。对照组试验中,采用25 μL 100 mmol/L pH8 Tris-HCl 代替HPSPR溶液,其他条件相同。按照下式计算抑制率:
式中,AS是HPSPR存在的吸光度,AC采用等体积的Tris-HCl缓冲液替代HPSPR的吸光度,ASE是采用等体积Tris-HCl缓冲液替代DPP-IV的吸光度,ACE是采用Tris-HCl替代DPP-IV和HPSPR的吸光度。
芝麻多肽的活性应用,ACE抑制率作为降血压指标,DPP-IV抑制率为降血糖指标,测试分析实施例1从芝麻蛋白中提取的芝麻多肽和实施例2采用人工合成的芝麻多肽HPSPR的降血压和降血糖活性,基本一致,均显示较强的降血压与降血糖能力(见表1)。
表1、实施例1和2所得芝麻多肽HPSPR的降血压与降血糖活性
表2、实施例1和2所得芝麻多肽HPSPR安全性预测
注:括号中数字为预测概率,a预测采用ToxinPred (https://webs.iiitd.edu.in/raghava/toxinpred/design.php),b采用admetSAR(http://lmmd.ecust.edu.cn/admetsar2/)。
由表2可以看出:HPSPR安全性高,预测无毒性、无致癌性,同时不会影响人体正常的生理机能。由图5可知:HPSPR通过氢键或疏水作用影响ACE中Asp377、Glu162、His353、Glu384、Gln281、Tyr523和Zn2+701活性位点,从而改变了ACE的空间位置,影响与血管紧张素的结合,起到降压作用。由图6可知:HPSPR通过氢键与疏水作用与DPP-IV中的Glu205,Glu206,Arg125, Tyr662活性位点作用,影响DPP-IV的机能,起到降糖功能。
以上所述仅为本发明的较佳实施例,凡依本发明申请专利范围所做的均等变化与修饰,皆应属本发明的涵盖范围。
Claims (8)
1.一种从芝麻蛋白中获得的具有降血压与降血糖活性的多肽,其特征在于,该多肽由5个氨基酸组成,其序列为:His-Pro-Ser-Pro-Arg。
2.一种权利要求1所述多肽的制备方法,其特征在于,采用固相合成法制备多肽。
3.一种从芝麻蛋白中提取权利要求1所述多肽的方法,其特征在于,包括下述步骤:
1)芝麻蛋白提取:
将除杂后的芝麻粉碎、脱脂,加入蒸馏水,调节pH到10-12,离心后,收集上清液,调节pH到4-5,离心,收集沉淀,水洗,冷冻干燥,获得芝麻蛋白;
2)蛋白酶解:
将步骤1)所得芝麻蛋白,按1g:10-30 mL加入蒸馏水,90-100 ℃加热15-40 min,冷却至室温,将pH值调至1.5-2.5,加入芝麻蛋白质量0.5-2.5%的胃蛋白酶,于30-50 ℃搅拌酶解2-6 h,随后调节pH至7.5-9.0,加入芝麻蛋白质量0.5-2.5%胰糜蛋白酶,于30-50 ℃酶解2-8 h,调节pH至4.0-4.5,离心取上清液,4-10℃低温备用;
3)分离纯化:
将步骤2)所得上清液调节pH到7.0,采用两级超滤处理,透过液采用纳滤进行脱盐浓缩,然后采用葡聚糖凝胶柱层析法分离纯化,收集保留时间在275-330 min的组分,冷冻真空干燥即得。
4.如权利要求3所述从芝麻蛋白中提取芝麻多肽的方法,其特征在于,步骤2)中所述胰糜蛋白酶由酶活之比为6:1的胰蛋白酶与胰凝乳蛋白酶组成。
5.如权利要求3所述从芝麻蛋白中提取芝麻多肽的方法,其特征在于,步骤3)中所述的两级超滤中,一级超滤所采用的超滤膜截留分子量为3000-10000 Da,二级超滤所采用的超滤膜截留分子量为1000 Da。
6.如权利要求3所述从芝麻蛋白中提取芝麻多肽的方法,其特征在于,步骤3)中葡聚糖凝胶柱层析法分离纯化条件:层析柱100×1.8 cm,流动相为蒸馏水,流速1.5 mL/min,检测波长为280 nm。
7.如权利要求6所述从芝麻蛋白中提取芝麻多肽的方法,其特征在于,步骤3)中选用的是葡聚糖G-10,粒径40-120 µm。
8.权利要求1所述多肽在制备降血压药物、食品、日化用品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010687265.9A CN111825754B (zh) | 2020-07-16 | 2020-07-16 | 一种从芝麻蛋白中获得的具有降血压与降血糖活性的多肽 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010687265.9A CN111825754B (zh) | 2020-07-16 | 2020-07-16 | 一种从芝麻蛋白中获得的具有降血压与降血糖活性的多肽 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111825754A CN111825754A (zh) | 2020-10-27 |
CN111825754B true CN111825754B (zh) | 2022-02-11 |
Family
ID=72924203
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010687265.9A Active CN111825754B (zh) | 2020-07-16 | 2020-07-16 | 一种从芝麻蛋白中获得的具有降血压与降血糖活性的多肽 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111825754B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115043920A (zh) * | 2022-06-27 | 2022-09-13 | 河南省农业科学院 | 一种芝麻蛋白来源且具有降血压与降血糖活性的多肽 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004250352A (ja) * | 2003-02-19 | 2004-09-09 | Marine Biotechnol Inst Co Ltd | リガンドとして有用なペプチド |
CN104558115A (zh) * | 2014-12-29 | 2015-04-29 | 浙江海洋学院 | 一种孔鳐鱼肉蛋白抗氧化多肽及其制备方法和用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI411441B (zh) * | 2003-03-18 | 2013-10-11 | Suntory Holdings Ltd | 血管收縮素轉化酶抑制性肽類 |
US20100119671A1 (en) * | 2007-04-20 | 2010-05-13 | Peter Philip Lankhorst | Peptide mixture as wine stabiliser |
CN110669099B (zh) * | 2018-10-09 | 2021-12-03 | 杏辉天力(杭州)药业有限公司 | 一种芝麻肽粉及其制备方法和用途 |
-
2020
- 2020-07-16 CN CN202010687265.9A patent/CN111825754B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004250352A (ja) * | 2003-02-19 | 2004-09-09 | Marine Biotechnol Inst Co Ltd | リガンドとして有用なペプチド |
CN104558115A (zh) * | 2014-12-29 | 2015-04-29 | 浙江海洋学院 | 一种孔鳐鱼肉蛋白抗氧化多肽及其制备方法和用途 |
Non-Patent Citations (2)
Title |
---|
3 种芝麻蛋白结构和性质比较研究;张国治等;《中国油脂》;20170725;第42卷(第7期);第55-58,64页 * |
Molecular cloning of 11S globulin and 2S albumin, the two major seed storage proteins in sesame;S S Tai et al;《JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY》;19991231;第47卷(第12期);第4932-4938页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111825754A (zh) | 2020-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107779489B (zh) | 一种具有抗氧化和ace抑制功能的蚕蛹蛋白肽 | |
CN104450839B (zh) | 具有ace抑制活性的米糠蛋白肽的制备方法 | |
CN113215212B (zh) | 一种具有抗氧化和ace抑制功能的大豆蛋白肽及其制备方法 | |
CN103052717A (zh) | 一种工业化生产玉米降压活性肽的方法 | |
CN103290086B (zh) | 具有ace抑制活性的绿豆蛋白肽及其制备方法与应用 | |
CN101584853B (zh) | 一种地龙蛋白多肽制剂 | |
CN110105431B (zh) | 一种芝麻多肽及其提取方法和在制备抗氧化和/或降血压药物中的应用 | |
CN111518164B (zh) | Ace抑制肽p2、其应用及其制备方法 | |
CN111825754B (zh) | 一种从芝麻蛋白中获得的具有降血压与降血糖活性的多肽 | |
CN111471086B (zh) | 芝麻多肽及其制备方法和应用 | |
CN112552394A (zh) | 一种牦牛降压肽及其制备方法 | |
CN116479077A (zh) | 高活性苦荞清蛋白降血压肽的制备方法 | |
CN106008669B (zh) | 一种榛仁ace抑制肽及其制备方法 | |
CN108840909B (zh) | 一种紫菜降压肽和紫菜降压肽提取物及应用 | |
CN103740797B (zh) | 一种利用高温花生粕制备高水解度功能性短肽的方法 | |
CN110734472B (zh) | 一种具有二肽基肽酶-4抑制活性的寡肽及其应用 | |
CN113072621B (zh) | 一种牦牛骨降血压肽及其制备方法与应用 | |
CN113912673A (zh) | 一种芝麻来源的低苦味ace抑制肽及其制备方法和应用 | |
CN110655553B (zh) | 一种芝麻来源的ace抑制肽、制备方法及其在制备降血压药物方面的应用 | |
CN107699601B (zh) | 一种具有ace抑制功能和dpp-iv抑制功能的蛹虫草蛋白肽 | |
CN115043920A (zh) | 一种芝麻蛋白来源且具有降血压与降血糖活性的多肽 | |
CN111499691B (zh) | Ace抑制肽p1、其应用及其制备方法 | |
CN117567562B (zh) | 南极磷虾ace抑制肽及其制备方法和应用 | |
CN112961212B (zh) | 一类ace抑制肽及其制备方法和应用 | |
CN109400687A (zh) | 一种西兰花蛋白来源的ace抑制肽及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |